Booster shot for CAR-T: drug aims to deepen response in tough myeloma cases
NCT ID NCT06523621
Summary
This study is for people with hard-to-treat multiple myeloma who had a less-than-ideal response to a CAR-T cell therapy called ide-cel. Researchers want to see if adding a drug called nivolumab can improve their response. The trial will enroll 50 adults who received ide-cel but did not achieve a deep remission, giving them nivolumab every 4 weeks to try to boost the CAR-T cells' effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27103, United States
Contact
Contact Email: •••••@•••••
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.